Xingli Tai: Innovative drug SAL0145 injection approved to commence clinical trials

People’s Financial News, March 24 — Xinli Tai (002294) announced on March 24 that the company has received the “Clinical Trial Approval Notice” issued by the National Medical Products Administration, approving the company’s self-developed innovative drug SAL0145 injection to conduct clinical trials for the MASH indication.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin